For the Inventor, By the Inventor

Enter assignee name

La Chaux-de-Fonds, Switzerland

Glenmark Specialty S.a.

USPTO Granted Patents = 26

% Expired Patents = 3.8

EPO Patents = 5

Trademarks = 5

Forward Citations = 44

Loading Chart...

Loading Chart...

35 inventors (with patents filed for the assignee):

Ulhas R Dhuppad (17 out of 24 patents)

Chandrakant Dhatrak (14 out of 15 patents)

Ashok Katkurwar (10 out of 12 patents)

4. Rajesh Ankam (10 out of 13 patents)

5. Neelima Khairatkar-Joshi (9 out of 44 patents)

6. Abhay Kulkarni (9 out of 11 patents)

7. Piyush Agarwal (9 out of 9 patents)

8. Patrick Keohane (9 out of 9 patents)

9. Sudeesh K Tantry (9 out of 9 patents)

10. Chad Oh (9 out of 9 patents)

11. Yashwant Gupta (9 out of 10 patents)

12. Vikram Mansingh Bhosale (9 out of 11 patents)

13. Dinesh Pradeep Wale (7 out of 8 patents)

14. Franciscus Koppenhagen (6 out of 7 patents)

15. Sunil Chaudhari (5 out of 7 patents)

Core Competencies:

Nasal Spray

Tiotropium

Mometasone

Olopatadine

Allergic Rhinitis

Nebulization

Inhaler

Pharmaceutical Composition

Fixed Dose

Dispensing Device

Formoterol

26 patents: Sort by Forward Citations

1. 12653833 - Nasal spray composition (2026-06-16),

2. 12558314 - Pressurized inhalation composition of tiotropium (2026-02-24),

3. 12303635 - Dispensing device and pharmaceutical composition for the treatment of rhinitis (2025-05-20),

4. 12064442 - Treatment of allergic rhinitis using a combination of mometasone and olopatadine (2024-08-20),

5. 11679210 - Dispensing device and pharmaceutical composition for the treatment of rhinitis (2023-06-20),

6. 11400101 - Treatment of allergic rhinitis using a combination of mometasone and olopatadine (2022-08-02),

7. 10765686 - Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine (2020-09-08),

8. 10758550 - Treatment of allergic rhinitis using a combination of mometasone and olopatadine (2020-09-01),

9. 10653683 - Tiotropium inhalation solution for nebulization (2020-05-19),

10. 10653661 - Treatment of allergic rhinitis using a combination of mometasone and olopatadine (2020-05-19),

11. 10646500 - Treatment of allergic rhinitis using a combination of mometasone and olopatadine (2020-05-12),

12. 10632109 - Tiotropium inhalation solution for nebulization (2020-04-28),

13. 10632108 - Tiotropium inhalation solution for nebulization (2020-04-28),

14. 10561672 - Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine (2020-02-18),

15. 10555903 - Nebulizable compositions of tiotropium and formoterol (2020-02-11),

Company Overview

Glenmark Specialty S.a., based in La Chaux-de-Fonds, Switzerland, is a prominent player in the pharmaceutical industry, focusing on the development and manufacturing of specialty medicines. The company is dedicated to advancing therapeutic solutions across various domains, including dermatology, oncology, and respiratory care. With a commitment to innovation, Glenmark leverages cutting-edge research and technology to address unmet medical needs, enhancing patient outcomes globally.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

26 Patents

#6 in La Chaux-de-Fonds

#502 in Switzerland

#24,806 in the World

La Chaux-de-Fonds, Switzerland

Glenmark Specialty S.a.

Forward Citations = 44

35 inventors:

Ulhas R Dhuppad (17 out of 24 patents)

Chandrakant Dhatrak (14 out of 15 patents)

Ashok Katkurwar (10 out of 12 patents)

4. Rajesh Ankam (10 out of 13 patents)

5. Neelima Khairatkar-Joshi (9 out of 44 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Glenmark Specialty S.a.. Retrieved from https://idiyas.com/company/glenmark-specialty-s-a

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…